7 Best Psychedelic Stocks to Buy According to Analysts
The article says the AdvisorShares Psychedelics ETF rose 31% over the past year, outpacing the Nasdaq and S&P 500. It cites optimism from Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary and notes J&J’s Spravato sales exceeded $1B in 2024, projected to reach $3B by 2027-28. It lists analyst-favored psychedelic stocks, including Definium Therapeutics (DFTX) and COMPASS Pathways (CMPS), with stated price-target upside of 28.15% and 38.57%.
How this was made
The 30-second read
Why it matters
For DFTX and CMPS, the actionable elements are the cited analyst PT/ratings and the referenced Phase 3 result details plus (for DFTX) a large underwritten offering. However, the article is primarily promotional and does not add comprehensive new primary disclosures beyond those snippets.
Market read
Traders may use the cited clinical durability and financing/regulatory outlook to reassess near-term sentiment and valuation risk, but the format limits incremental decision value.
What to watch
The article does not quantify probability of approval, competitive landscape, or near-term cash runway, which can dominate risk for pre-commercial psychedelic developers.
Background
The piece frames psychedelics as moving toward mainstream healthcare, citing ETF performance and regulatory optimism, then lists “best buys” with analyst upside screens.
Ticker impact
Canaccord cut DFTX price target to $58 but reaffirmed Buy after strong Phase 3 EMERGE results and a $805M financing.
Bias modestly positive over days, with volatility around financing dilution and ongoing trial/commercial milestones.
The article cites both clinical Phase 3 strength and a sizable underwritten offering that increases cash but raises share count, while the analyst PT was reduced.
Oppenheimer reaffirmed Outperform and $20 PT after new Phase 3 COMP006 26-week results supporting sustained COMP360 efficacy and regulatory path.
Bias positive over the next several sessions as traders price improved regulatory outlook and potential 2027 launch timing.
The text provides specific trial outcomes (Week 6 response, maintained through Week 26) and links them to an NDA timing thesis.
Market effects
Reinforces the narrative that late-stage psychedelic efficacy durability and regulatory progress are driving investor interest.
Limited direct regional impact; both subjects are US-listed biotech names with global clinical/regulatory relevance.
Supports broader global mental-health innovation sentiment, but no new policy or cross-border deal is disclosed.
Counterpoint
Capital raises and dilution risk can offset clinical optimism, and analyst PT changes may signal valuation sensitivity rather than upside certainty.
Key entities
- companyDefinium Therapeutics
NASDAQ-listed psychedelic/psychoplastogenic developer; cited for Phase 3 EMERGE results and a $805M underwritten public offering.
- companyCOMPASS Pathways
NASDAQ-listed psychedelic therapy developer; cited for Phase 3 COMP006 26-week results and an NDA timing thesis.
